FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602917953> ?p ?o ?g. }

• W2602917953 endingPage "8206" @default.
• W2602917953 startingPage "8195" @default.
• W2602917953 abstract "When activated through toll-like receptors (TLRs), macrophages generate IL-33, an IL-1 family member that induces innate immune responses through ST2 signaling. LPS, a TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and microsomal PGE2 synthase 1 (mPGES-1) (1Duan Y. Chen F. Zhang A. Zhu B. Sun J. Xie Q. Chen Z. Aspirin inhibits lipopolysaccharide-induced COX-2 expression and PGE2 production in porcine alveolar macrophages by modulating protein kinase C and protein tyrosine phosphatase activity.BMB Rep. 2014; 47: 45-50Crossref PubMed Scopus (16) Google Scholar). We demonstrate that IL-33 production by bone marrow-derived murine macrophages (bmMFs) requires the generation of endogenous PGE2 and the intrinsic expression of EP2 receptors to amplify NF-κB-dependent, LPS-induced IL-33 expression via exchange protein activated by cAMP (EPAC). Compared with WT cells, bmMFs lacking either mPGES-1 or EP2 receptors displayed reduced LPS-induced IL-33 levels. A selective EP2 agonist and, to a lesser extent, EP4 receptor agonist potentiated LPS-induced IL-33 generation from both mPGES-1-null and WT bmMFs, whereas EP1 and EP3 receptor agonists were inactive. The effects of PGE2 depended on cAMP, were mimicked by an EPAC-selective agonist, and were attenuated by EPAC-selective antagonism and knockdown. LPS-induced p38 MAPK and NF-κB activations were necessary for both IL-33 production and PGE2 generation, and exogenous PGE2 partly reversed the suppression of IL-33 production caused by p38 MAPK and NF-κB inhibition. Mice lacking mPGES-1 showed lower IL-33 levels and attenuated lung inflammation in response to repetitive Alternaria inhalation challenges. Cumulatively, our data demonstrate that endogenous PGE2, EP2 receptors, and EPAC are prerequisites for maximal LPS-induced IL-33 expression and that exogenous PGE2 can amplify IL-33 production via EP2 and EP4 receptors. The ubiquitous induction of mPGES-1-dependent PGE2 may be crucial for innate immune system activation during various IL-33 driven pathologic disorders. When activated through toll-like receptors (TLRs), macrophages generate IL-33, an IL-1 family member that induces innate immune responses through ST2 signaling. LPS, a TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and microsomal PGE2 synthase 1 (mPGES-1) (1Duan Y. Chen F. Zhang A. Zhu B. Sun J. Xie Q. Chen Z. Aspirin inhibits lipopolysaccharide-induced COX-2 expression and PGE2 production in porcine alveolar macrophages by modulating protein kinase C and protein tyrosine phosphatase activity.BMB Rep. 2014; 47: 45-50Crossref PubMed Scopus (16) Google Scholar). We demonstrate that IL-33 production by bone marrow-derived murine macrophages (bmMFs) requires the generation of endogenous PGE2 and the intrinsic expression of EP2 receptors to amplify NF-κB-dependent, LPS-induced IL-33 expression via exchange protein activated by cAMP (EPAC). Compared with WT cells, bmMFs lacking either mPGES-1 or EP2 receptors displayed reduced LPS-induced IL-33 levels. A selective EP2 agonist and, to a lesser extent, EP4 receptor agonist potentiated LPS-induced IL-33 generation from both mPGES-1-null and WT bmMFs, whereas EP1 and EP3 receptor agonists were inactive. The effects of PGE2 depended on cAMP, were mimicked by an EPAC-selective agonist, and were attenuated by EPAC-selective antagonism and knockdown. LPS-induced p38 MAPK and NF-κB activations were necessary for both IL-33 production and PGE2 generation, and exogenous PGE2 partly reversed the suppression of IL-33 production caused by p38 MAPK and NF-κB inhibition. Mice lacking mPGES-1 showed lower IL-33 levels and attenuated lung inflammation in response to repetitive Alternaria inhalation challenges. Cumulatively, our data demonstrate that endogenous PGE2, EP2 receptors, and EPAC are prerequisites for maximal LPS-induced IL-33 expression and that exogenous PGE2 can amplify IL-33 production via EP2 and EP4 receptors. The ubiquitous induction of mPGES-1-dependent PGE2 may be crucial for innate immune system activation during various IL-33 driven pathologic disorders." @default.
• W2602917953 created "2017-04-07" @default.
• W2602917953 creator A5008622191 @default.
• W2602917953 creator A5027299023 @default.
• W2602917953 creator A5057552794 @default.
• W2602917953 creator A5083927736 @default.
• W2602917953 date "2017-05-01" @default.
• W2602917953 modified "2023-10-14" @default.
• W2602917953 title "Endogenous prostaglandin E2 amplifies IL-33 production by macrophages through an E prostanoid (EP)2/EP4-cAMP-EPAC-dependent pathway" @default.
• W2602917953 cites W1966971483 @default.
• W2602917953 cites W1984079217 @default.
• W2602917953 cites W1994168958 @default.
• W2602917953 cites W1998846885 @default.
• W2602917953 cites W2020887684 @default.
• W2602917953 cites W2021875427 @default.
• W2602917953 cites W2027462139 @default.
• W2602917953 cites W2035213809 @default.
• W2602917953 cites W2037174379 @default.
• W2602917953 cites W2043099698 @default.
• W2602917953 cites W2058034672 @default.
• W2602917953 cites W2069228549 @default.
• W2602917953 cites W2071815411 @default.
• W2602917953 cites W2072829754 @default.
• W2602917953 cites W2089560141 @default.
• W2602917953 cites W2103572248 @default.
• W2602917953 cites W2118901290 @default.
• W2602917953 cites W2121327269 @default.
• W2602917953 cites W2121674630 @default.
• W2602917953 cites W2122508494 @default.
• W2602917953 cites W2125758213 @default.
• W2602917953 cites W2129161823 @default.
• W2602917953 cites W2152588224 @default.
• W2602917953 cites W2157710399 @default.
• W2602917953 cites W2166611766 @default.
• W2602917953 cites W2168612089 @default.
• W2602917953 cites W2220883354 @default.
• W2602917953 cites W2264448113 @default.
• W2602917953 cites W2306416367 @default.
• W2602917953 cites W2408019941 @default.
• W2602917953 doi "https://doi.org/10.1074/jbc.m116.769422" @default.
• W2602917953 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5437228" @default.
• W2602917953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28341741" @default.
• W2602917953 hasPublicationYear "2017" @default.
• W2602917953 type Work @default.
• W2602917953 sameAs 2602917953 @default.
• W2602917953 citedByCount "31" @default.
• W2602917953 countsByYear W26029179532018 @default.
• W2602917953 countsByYear W26029179532019 @default.
• W2602917953 countsByYear W26029179532020 @default.
• W2602917953 countsByYear W26029179532021 @default.
• W2602917953 countsByYear W26029179532023 @default.
• W2602917953 crossrefType "journal-article" @default.
• W2602917953 hasAuthorship W2602917953A5008622191 @default.
• W2602917953 hasAuthorship W2602917953A5027299023 @default.
• W2602917953 hasAuthorship W2602917953A5057552794 @default.
• W2602917953 hasAuthorship W2602917953A5083927736 @default.
• W2602917953 hasBestOaLocation W26029179531 @default.
• W2602917953 hasConcept C126322002 @default.
• W2602917953 hasConcept C134018914 @default.
• W2602917953 hasConcept C170493617 @default.
• W2602917953 hasConcept C178592051 @default.
• W2602917953 hasConcept C185592680 @default.
• W2602917953 hasConcept C2777956040 @default.
• W2602917953 hasConcept C2778938600 @default.
• W2602917953 hasConcept C51551487 @default.
• W2602917953 hasConcept C55493867 @default.
• W2602917953 hasConcept C57074206 @default.
• W2602917953 hasConcept C62478195 @default.
• W2602917953 hasConcept C71924100 @default.
• W2602917953 hasConcept C86803240 @default.
• W2602917953 hasConcept C95444343 @default.
• W2602917953 hasConceptScore W2602917953C126322002 @default.
• W2602917953 hasConceptScore W2602917953C134018914 @default.
• W2602917953 hasConceptScore W2602917953C170493617 @default.
• W2602917953 hasConceptScore W2602917953C178592051 @default.
• W2602917953 hasConceptScore W2602917953C185592680 @default.
• W2602917953 hasConceptScore W2602917953C2777956040 @default.
• W2602917953 hasConceptScore W2602917953C2778938600 @default.
• W2602917953 hasConceptScore W2602917953C51551487 @default.
• W2602917953 hasConceptScore W2602917953C55493867 @default.
• W2602917953 hasConceptScore W2602917953C57074206 @default.
• W2602917953 hasConceptScore W2602917953C62478195 @default.
• W2602917953 hasConceptScore W2602917953C71924100 @default.
• W2602917953 hasConceptScore W2602917953C86803240 @default.
• W2602917953 hasConceptScore W2602917953C95444343 @default.
• W2602917953 hasFunder F4320332161 @default.
• W2602917953 hasIssue "20" @default.
• W2602917953 hasLocation W26029179531 @default.
• W2602917953 hasLocation W26029179532 @default.
• W2602917953 hasLocation W26029179533 @default.
• W2602917953 hasLocation W26029179534 @default.
• W2602917953 hasOpenAccess W2602917953 @default.
• W2602917953 hasPrimaryLocation W26029179531 @default.
• W2602917953 hasRelatedWork W1922492444 @default.
• W2602917953 hasRelatedWork W2004726042 @default.
• W2602917953 hasRelatedWork W2027913950 @default.
• W2602917953 hasRelatedWork W2034583712 @default.
• W2602917953 hasRelatedWork W2050423574 @default.

• next